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ABSTRACT 
The paper evaluates the hypothesis that cannabis abuse is associated with a broad 
range of psychiatric disorders in India, an area with relatively high prevalence of 
cannabis use. Retrospective case-note review of all cases with cannabis related 
diagnosis over a 11 -year period, for subjects presenting to a tertiary psychiatric 
hospital in southern India was carried out. Information pertaining to socio-
demographic, personal, social, substance-use related, psychiatric and treatment 
histories, was gathered. Standardized diagnoses were made according to Diagnostic 
Criteria for Research of the World Health Organization, on the basis of information 
available. 
Cannabis abuse is associated with widespread psychiatric morbidity that spans the 
major categories of mental disorders under the ICD-10 system, although proportion 
of patients with psychotic disorders far outweighed those with non-psychotic 
disorders. Whilst paranoid psychoses were more prevalent, a significant number of 
patients with affective psychoses, particularly mania, was also noted. 
Besides being known as either the causative agent or a potent risk factor in cases 
of paranoid psychoses, cannabis appears to have similar capabilities with regard to 
affective psychoses, particularly in cases of mania. It is suggested that cannabis has 
the potential to act as a "life event stressor" amongst subjects vulnerable to develop 
affective psychoses and the possible aetiopathogenesis of such a finding is discussed. 
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INTRODUCTION 
Cannabis is one of the most frequently 
abused psychoactive drugs (Grinspoon and 
Bakalar 1993). Psychiatric disturbances 
associated with cannabis use range from 
minor psychological responses such as 
anxiety and panic (Thomas 19%), to 
depressive disorders (Troisi et al 1998), the 
more serious mental illnesses such as the 
putative 'cannabis psvehosis' (Talbott and 
Teaguc 1969), acute functional psvehosis 
(Johns 21KM), chronic psychosis (Ghodse 
1986) and the poorly validated entity of 
'•motivational svndrome (Hall ct al 1999). 
The nature of association and the direction 
of causality between cannabis use and 
various mental disorders await elucidation 
(Thomas 1993). The strongest evidence of 
a specific contributory role of cannabis use 
exists only in relation to schizophrenia 
(Andreasen et al 1987). 
India has a long tradition of cannabis 
use, which is often socially sanctioned 
(National Institute of Social Defense 1992). 
The association between cannabis use and 
mental disorders has been recorded for well 
over a century (Indian Hemp Commission 
Report 1894). Whilst considerable attention 
has been paid to the association between 
cannabis use and psychotic disorders (Basu 
et al 1999, Thacore and Shukla 1976, 
Chopra and Smith 1974), relatively little is 
known about the impact of cannabis abuse 
on wider psychiatric morbidity. We present 
a retrospective study as preliminary 
exploration to evaluate the hypothesis that 
cannabis abuse will be associated with a 
broad range of psychiatric disorders, 
through a case-note review of patients 
abusing cannabis who presented to a large 
tertiary psychiatric hospital in south India. 
We also explored the pattern of cannabis 
use by this population. 
METHODS 
The Catchment Population: The study 
was conducted at a tertiary referral center 
in Bangalore, catering to a large catchment 
area. All patients receive a diagnostic code 
according to the criteria laid down in 
successive revisions of the International 
Classification of Diseases - ICD-9, (prior to 
1992) and ICD-10 (thereafter). In keeping 
with WHO recommendations, all comorbid 
psychiatric diagnoses are coded for each 
patient. 
Sample: Selected case-notes with any 
cannabis related diagnosis were identified 
for the period between 1984-1994. 
Data: Information was recorded for 
socio-demographic data, history of substance 
use and other clinical history variables. 
Socio-demographic variables included 
subject's age, sex, completed years of_. 
education, and occupation. Substance use 
variables were age of onset of cannabis use, 
reason for initiation, duration of cannabis 
use, duration of daily use, temporal sequence 
of onset of psychiatric disorder in relation 
to cannabis use, and use of any other 
psychoactive substance prior to and following 
the onset of cannabis use. Further, family 
history of substance use and mental illness, 
and the reason for establishing contact with 
the hospital were recorded. Psychopathology 
variables recorded included delusions 
(reference, persecution, grandiosity, infidelity 
and others), hallucinations in any modality, 
thought disorder (including flight of ideas), 
thought alienation phenomena, psychomotor 
activity, mood disturbance, level of 
sensorium, cognitive deficits and treatment 
offered. 
< 
Information pertaining to 
psychopathology was recorded in the 
following manner: 
a) for patients with 1 -2 contacts during the 
study period, all phenomena displayed 
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during each of these contacts was 
recorded. In doing so, the 'present 
state' format for recording 
psychopathology was adopted. 
b) for patients with 3-5 contacts, symptoms 
contained in the most recent contact 
were recorded along with symptoms of 
a similar type but with a more 
characteristic symptom profile, 
employing the notion of a 'representative 
episode'. Where the most recent episode 
of symptoms was different from the 
representative episode (for example, 
manic episode manifested upon a 
depressive representative episode) both 
sets of symptoms were recorded. 
c) In cases with more than 5 contacts, all 
varieties of symptoms e.g. psychotic, 
affective and neurotic, as had been 
displayed by the patient, were recorded. 
Where there were two periods or 
episodes with different types of 
symptoms, these were rated as though 
they were sub-episodes of one extended 
episode employing the notion of 
symptoms experienced in the 'lifetime 
before'. This pattern is an acceptable 
method of symptom recording in order 
to generate diagnoses [World Health 
Organization 1993a]. All diagnoses 
were made on the basis of criteria laid 
down in the Diagnostic Criteria for 
Research, DCR, (World Health 
Organization 1993 b). 
RESULTS 
Socio-demographic data 
Two hundred and forty four notes were 
identified as having a cannabis related 
diagnosis. AU 244 subjects were male. 
Their mean age was 30 years (S.D. ± 9.7; 
Range = 18-82 years) and 53% were single 
(109/204; data unrecorded = 40). They had 
on average 9.7 years (S.D. ± 9.8) of education 
and 45% had received between 5-10 years 
of formal education. Sixty-two percent of 
patients were employed with representation 
of professional, skilled and unskilled workers 
being 13%, 27% and 22% respectively. 
Substance use history 
The mean age of initiation of cannabis 
use was 22.4 years (S.D. + 8.4 years; Range 
= 10-65 years). Forty-three percent (9=105 
had started using cannabis during the second 
decades of their lives. Eighty-nine (36%) 
began use during the third decade whilst 
twenty-five (10%) did so in the fourth 
decade. For the rest, onset of use was even 
later. Where information pertaining to 
reasons for cannabis use was recorded (n 
= 115; 47%), 57% cited recreational and 
experimental use, 12% attributed onset to 
a dysphoric mood state while 11% cited 
peer pressure as the primary reason. 
Data was unavailable for total duration 
of non-continuous (regular but not daily) 
and continuous (daily) cannabis use in 32 
(13%o) and 141 (58%) cases respectively. 
The mean duration of non-continuous use 
of cannabis was 80 months (S.D. +. 71 
months) while the duration of continuous 
use was 49 months (S.D. ± 50 months). 
Amongst daily users, 32 (31%) subjects had 
been using cannabis for less than 2 years, 
44 (43 %) patients had been using it 
between 2-5 years and 27 (26 %) patients 
had consumed it for over 5 years. 
Relation of cannabis use to 
onset of psychiatric disorders 
In 127 patients (52%), a psychiatric 
disorder had occurred following cannabis 
use while for 18 patients (7%), psychiatric 
disturbance had preceded the onset of 
cannabis use. Data were unavailable for 99 
patients (41%). For 67% of patients cannabis 
was the first drug of abuse in their substance 
use life-trajectories. Alcohol and opioids 
were the initial substance of abuse in 29% 
and 4% patients respectively. Amongst 
those using cannabis on a continuous basis, 
15% also used polysubstance (cannabis, 
alcohol and opioids for this study) while 
11%) and 9% used only alcohol and opioids 
respectively. Thus, 35% of cannabis users 
also used other substances concurrendy, 
whilst for the remaining 65% cannabis 
remained the only substance of use. Data 
on homotypic comorbidity (other comorbid 
substance use disorders) was unavailable for 
24 cases (see table 2). 
TABLE I : Socio-demographic and substance use variables 
Variable (N=244)  Mean  S.D.  Range 
Age of patient 
Age of onset of cannabis use 
Duration of 
non-continuous cannabis use 
Duration of 
continuous cannabis use 
30 years 
22.4 years 
80 months 
49 months 
+_9.7 years 
+_ 8.4 years 
+_ 71 months 
+_ 50 months 
18-82 years 
10-65 years 
1-244 months 
1-240 months 
TABLE 2 : Temporal relation between cannabis and other drug use 
(n =244) 
Opiates 
Combination of the above 
None 
Not known 
Substance 
Following 
n 
64 
8 
2 
146-
24 
used 
Cannabis 
% 
29' 
4 
1 
66 
Preceding 
n 
1 
0 
34 
139 
24 
cannabis use 
% 
11 
9 
16 
63 
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Family history 
Data on family history were available in 
202 (83%) subjects. 33 subjects (16%) had 
a positive family history of a psychiatric 
disorder and 48 (24%) had a positive family 
history of substance abuse. Twenty-seven 
percent of patients with non-psychotic 
illnesses had a positive family history followed 
by subjects with affective psychoses (26%), 
paranoid psychoses including schizophrenia 
(18%), cannabis psychosis (16%) and 
substance misuse disorders (9%). Patients 
with only substance misuse disorders had 
the highest rate of family history of 
substance misuse (32%), followed by subjects 
with non-psychotic illness (29%), paranoid 
Psychopathology 
Delusional thinking was reported in 105 
patients (43%). Persecutory delusions were 
the commonest (26%) followed by grandiose 
(22%) and referential (9%) delusions. Forty-
one percent of patients experienced 
hallucinations, most commonly in the 
auditory modality (25%). Thought disorder, 
including 'flight of ideas', was recorded in 
26 patients (11%). Elated mood (23%) was 
more common than depressed mood (16%), 
in patients with affective disturbances. 
Thought alienation phenomena such as 
thought broadcasting, thought insertion and 
thought withdrawal were reported in 11 
TABLE 3 : Family history of mental illness and substance misuse 
Diagnostic groups Family History of Family History of Substance 
Mental Illness Misuse 
(data unavailable n=42, 17%) (data unavailable n=4l, 17%) 
Non-psychotic 
Affective psychosis 
(DCR rubric of F30-39) 
Non-affective psychosis 
(DCR rubric of F20-29) 
Cannabis psychosis 
Substance misuse disorder 
Total 
n 
4/15 
8/31 
7/39 
8/51 
6/65 
33/202 
% 
27 
26 
18 
16 
9 
16 
n 
4/14 
4/30 
9/41 
9/50 
22/68 
48/203 
% 
29 
13 
22 
18 
32 
24 
psychoses (22%), cannabis psychosis (18%) 
and affective psychosis (13%). 
Reason for help seeking 
For 110 patients (56%) (Data unavailable: 
n= 47; 19%), display of abnormal behavior 
usually noted by family members formed 
the reason for establishing contact with the 
clinical services. A third of the patients 
contacted the hospital for relief from 
distressing withdrawal symptoms of alcohol 
and opioid withdrawal. Subjectively reported 
depressed mood was the presenting 
complaint in 11% patients. 
(4%) cases. Increased psychomotor activity 
(n=ll;4%), pressure of speech (n =9; 3%) 
and a combination of the two (n=7; 2%) 
were also evident in a small proportion of 
patients.. Bizarre behaviour that included 
such acts as smearing faeces, spitting, 
inappropriate and vacuous laughter, living in 
rubbish pits, taking off one's clothes, self 
mutilation, mutism, and posturing was 
reported in 31 (13%) cases. Catatonic 
symptoms were included amongst these. 
The case notes also recorded ten patients 
as having clouding of consciousness (4%), 
and seven patients (3%) with cognitive 
deficits 
Diagnosis 
Two types of comorbidity were identified 
in this cohort. Cannabis use disorder/s was 
either associated with other substance use 
disorder/s (but not with substance use 
related mental disorder/s) or with 
independent psychiatric disorder/s, i.e. non-
substance use related. The former was 
referred to as homotypic while the latter as 
heterotypic comorbidity [Degenhardt et al 
2001]. 
a) Substance abuse comorbidity 
(Homotypic comorbidity): 
There were in all eight different types of 
substance related diagnoses, other than 
cannabis-related diagnoses, in the total cohort 
(see table 4). There were 144 cases of 
cannabis dependence, 95 cases of harmful 
use (abuse) and five cases of acute 
intoxication. One hundred nine patients 
(47%) also received another substance misuse 
disorder diagnosis, which included forty-
nine cases of alcohol abuse (n=23) or 
dependence (n=26), thirty-six cases of 
polysubstance abuse (n=13) or dependence 
(n=23) and thirteen cases of opioid 
dependence. Polysubstance abuse/ 
dependence was recorded in those abusing 
three different substances concurrendy: 
cannabis, alcohol and opioids. There were 
no case of amphetamine, benzodiazepine, 
cocaine, ecstasy, LSD, inhalant or steroid 
abuse. The prevalence of nicotine and 
caffeine use was not recorded. Substance 
misuse/dependence was the only psychiatric 
diagnosis in eighty cases (34%). This 
number may appear to be smaller than what 
the preceding figures suggest as patient with 
more than one substance abuse/dependence 
were counted more than once under the 
respective headings. For instance a patient 
with cannabis abuse/dependence who was 
Comorbidity of Cannabis abuse 
I Cannabis 
diagnosis+Heterotypic 
comorbidity 
) Cannabis diagnosis + 
Homotypic comorbidity 
I Cannabis diagnosis + 
Homotypic comorbidity + 
Heterotypic comorbidity 
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TABLE 4 : Psychiatric morbidity in patients abusing cannabis 
Diagnosis 
Cannabis induced psychosis 
Schizophrenia 
Delusional disorder 
Other non organic psychotic disorders 
B.A.D-mania with psychosis 
B.A.D.- severe psychotic depression 
Severe psychotic depression 
Hypomania 
Mild depression 
Moderate depression 
Other depressive disorder 
Cyclothymia 
Dysthymia 
Generalized anxiety disorder 
Adjustment reaction - prolonged depression 
Trance and possession disorder 
Dissocial Personality disorder 
Pathological gambling 
Exhibitionism 
Mild Mental Retardation 
Cannabis induced unspecified mental 
& behavior disorder 
Substance use/dependence only 
Total 
No. of cases 
51 
35 
5 
18 
30 
1 
4 
4 
1 
3 
1 
1 
2 
1 
1 
1 
1 
1 
1 
1 
1 
80 
244 
% (N=244) 
21 
14 
2 
7 
12 
0.4 
2 
2 
0.4 
1 
0.4 
0.4 
1 
0.4 
0.4 
0.4 
0.4 
0.4 
0.4 
0.4 
0.4 
34 
100 
also abusing alcohol and opioids was 
coded under cannabis abuse and 
polysubstance abuse respectively. 
b) Independent psychiatric disorder 
comorbidity (Heterotypic comorbidity) 
Twenty-one heterotypic comorbid 
psychiatric diagnoses were made for 164 
patients (67%), i.e. having a comorbid 
psychiatric disorder. Psychotic disorders 
were experienced by 144 patients (88% of 
Heterotypic comorbidity 
I Paranoid psychosis 
I Cannabis psychosis 
I Affective psychosis 
I Non-psychotic disorders 
Heterotypic comorbidity of Cannabis 
use 
those with comorbid psychiatric disorders), 
while 20 patients experienced a non-psychotic 
illness (12%). The group of patients with 
psychotic disorders was made up of those 
suffering with paranoid psychosis including 
schizophrenia (n=58; 40%), cannabis 
psychosis (n=51; 35%) and affective 
psychosis (n=35; 25%). Depressive and 
anxiety disorders (n=9; 45%) were the 
largest contributors to the numbers of those 
with non-psychotic disorders. 
Cannabis psychosis was the commonest 
diagnosis amongst those with psychotic 
disorders. Six different subtypes of cannabis 
psychosis were diagnosed, the commonest 
subtype being a mania-like psychosis (n=22) 
with grandiose delusions, elated mood and 
increased psychomotor activity. A 
predominandy schizophrenia-like psychotic 
state (n=8) and a predominandy delusional 
state (n=6) were seen more often than a 
further six cases of a predominantly 
hallucinatory psychosis. Five subjects 
presented with a polymorphic and rapidly 
changing clinical picture characterized by 
delusions, hallucinations and mood 
disturbance, most commonly elation. A 
further four cases displayed an admixture 
of paranoia, grossly disorganized behavior, 
fleeting hallucinations and delusions and 
were diagnosed as mixed psychotic state. 
The latter diagnosis was made by a process 
of exclusion of other diagnostic subtypes. 
Significandy, there was no case of a 
predominandy depressive psychotic state 
Psychotic disorders 
I Cannabis psychosis 
I Schizophrenia 
I B.A.D. • Mania 
I Other non-organic 
psychosis 
I Delusional disorder 
I psychotic depression 
I B.A.I). - Psychotic 
depression 
Psychotic disorders associated 
with cannabis use 
I Manic 
I Schizophrenia-like 
I Delusional 
I Hallucinatory 
I polymorphic 
I Mixed 
Subtypes ol cannabis psychosis 
Subtypes of cannabis psychosis 
that could be attributed to cannabis abuse. 
Twelve patients with cannabis psychosis had 
consumed substances other than cannabis 
including alcohol (10 cases) and two cases 
of polysubstance abuse/dependence. These 
were diagnosed as cannabis psychosis 
because of a temporal link between cannabis 
use and onset of psychosis. 
Treatment given 
About half the patients (49.5%) received 
antipsychotic medication (49.5%); twenty-
three patients (9%) received a mood-
stabilizing agent while 12 (%) were prescribed 
antidepressants. 
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DISCUSSION 
This study has a large patient sample of 
chronic and heavy cannabis users coming 
from a wide geographical catchment area 
including urban, peri-urban, sub-rural, and 
rural populations. The sample is 
representative of all strata of the society. 
The strengths of the study included data 
collected at an academic institute with a 
tradition of good record keeping and 
diagnostic coding. A manual search in 
addition to electronic search was carried out 
to locate all case-notes thereby minimizing 
the chances of missing cases. Down-rating 
the aetiologies! role of cannabis in favour 
of a functional diagnosis would have further 
reduced any spurious attribution of mental 
disorders solely to cannabis use. 
a) Heterotypic Comorbidity 
Our results suggest that heavy and chronic 
use of cannabis can both cause a cannabis-
induced psychosis and be associated with 
functional psychoses. Broadly, the nature 
of psychosis associated with heavy cannabis 
use is non-specific in that it includes both 
paranoid and affective psychosis but also a 
polymorphic disorder that cannot be 
categorized within either of the two groups. 
A smallet proportion of patients also 
developed non-psychotic disorders. The 
presence of a wide variety of psychiatric 
disorders associated with cannabis abuse 
therefore confirmed the study hypothesis. 
The rate of psychiatric morbidity is 
comparable to earlier reports [Troisi et al 
1998, Weller and Halikas 1985]. 
b) Cannabis and Manic Psychosis 
The most significant finding of the study 
was the association of cannabis abuse with 
development of manic disorder. Whilst 
there are previous smaller reports of a 
possible association between cannabis use 
and mania, [Dhunjibhoy 1930, Rottanburg 
et al 1982, Carney et al 1984, Harding and 
Knight 1973] we believe that our study is 
the first one to confirm this relationship in 
a sizable number of patients. In our cohort, 
some patients with a past history of mania 
and cannabis abuse appeared to become 
sensitized to the effects of cannabis over 
a period of time so that for subsequent 
episodes of mania there appeared to be a 
progressive decrease in the time gap between 
re-onset of cannabis use and onset of 
mania. In other words, the relative 
shortening of time to relapse following 
reintroducrion of cannabis use in successive 
episodes in this select group of patients 
appeared analogous to the process of 
'kindling' [Post et al 1989, Post et al 1982]. 
By 'hastening' manic relapses, cannabis 
appeared to act as a precipitant, akin to the 
"life-event stressor" first suggested as a 
triggering mechanism in cases of 
schizophrenia [Andreasson et al 1987]. The 
association between cannabis abuse and 
mania gains further support from a recent 
study wherein cannabis use during follow-
up of 50 new-onset bipolar disorder patients 
was associated with the experience of mania, 
whilst alcohol abuse was linked to the 
experience of depression [Strakowski et al 
2000]. 
There may be possible biological 
explanations for the association between 
cannabis abuse and mania. Delta-9-
tetrahydrocannabinol (THC), the active 
ingredient of cannabis, produces euphoria 
[Brill and Nahas 1984]. Under laboratory 
conditions high doses of THC have been 
shown to produce visual and auditory 
hallucinations, delusions, thought disorder 
and symptoms of hypomania in normal 
volunteers [Georgotas and Zeidenberg 1979]. 
Recent evidence also suggests that 
cannabinoid receptors, especially CB-1, 
located in substantia nigra, hippocampus, 
cerebellum and striatum, may be 
neuromodulatory by decreasing the uptake 
of GABA and dopamine, thereby 
potentiating their actions [D'Souza and 
Kosten 2001]. Further prospective and 
case-control studies, which control for other 
substance misuse are needed to elucidate 
this further. 
ii) Cannabis Psychosis 
Our results suggest that besides the 
triggering effect of cannabis in established 
bipolar disorders, cannabis psychoses can 
also present as a manic episode. We also 
found other psychotic presentations 
suggesting that cannabis psychosis can 
present as schizophrenia-like, predominantly 
delusional or hallucinatory, as affective 
psychosis or as a polymorphic and rapidly 
changing psychosis. We could not confirm 
the previous suggestions that the presence 
of confusional state is a hallmark of cannabis 
psychosis [Johns 2001, Chopra and Smith 
1974, Chaudhry et al 1991, Tennant and 
Groesbeck 1972, Goel and D'Netto 1975] 
since only three patients in this study 
displayed a confusional state. The DCR 
position, which does not prioritize this 
particular feature to a position of primacy 
in making a diagnosis of cannabis psychosis, 
is therefore validated. 
iii) Cannabis and Schizophrenic 
Psychosis 
Our results confirm the association 
between cannabis abuse and paranoid 
psychoses, especially schizophrenia. 
However, even some of these cases have 
prominent affective features, consistent with 
previous reports [Thacore and Shukla 1976, 
Rottanburg et al 1982, Tsuang et al 1982]. 
In addition, in a substantial proportion of 
our cases, only a diagnosis of 'other non-
organic psychotic disorders' (F29 category) 
[World Health Organization 1993a] could be 
made on account of bizarre symptomatology, 
particularly grossly disorganized behavior. 
Whilst the diagnosis of catatonic 
schizophrenia had been made for several of 
these patients by treating clinical teams, this 
diagnosis was found unsupported by DCR 
criteria, which specify that catatonic 
symptoms are not diagnostic of 
schizophrenia and may be provoked by 
other aetiologies including alcohol or drugs 
[World Health Organization 1993b]. 
b) Homotypic Comorbidity: 
Cannabis has been known as a 'gateway 
drug', and recent evidence suggests that 
even after controlling for a wide range of 
known risk factors for illicit drug use, 
cannabis use is associated with an increased 
risk of progression to other illicit drug use 
[Fergusson and Horwood 2000]. Our study 
confirms this since many subjects had 
alcohol, opioid and polysubstance abuse 
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and dependence in this group. Cannabis 
was die first drug of use in the substance 
use life-trajectories of two-thirds of this 
population, the remaining third starting with 
alcohol or opioids. However, for two-thirds 
of the whole cohort cannabis remained the 
only drug of abuse. Whilst this may appear 
contradictory to the foregoing, we believe 
diat it is not inconsistent for people to 
progress from cannabis use to other illicit 
drugs in experimental ways, but to continue 
to preferentially use cannabis in a dependant 
manner, thereby confirming that in countries 
such as India that have a tradition of 
cannabis use, the widespread use of other 
substances is limited [Basu et al 1994]. 
The study findings are limited by the 
cohort being exclusively male, die lack of 
corroborative urine samples, possible recall 
bias and under-reporting by patients and, 
lack of any structured assessments, leading 
to reliance on case-note data alone. 
CONCLUSIONS 
Chronic and heavy abuse of cannabis in 
hospital attending patients in India is 
associated with widespread psychiatric 
morbidity. The onset of cannabis use 
begins at a relatively early age and heralds 
the experimentation with other psychoactive 
drugs. For the majority, however, cannabis 
remains the only drug of abuse. Experience 
of a psychotic illness is one of the major 
adverse effects of heavy cannabis use, 
particularly in those that present to 
psychiatric hospitals. Whilst our study 
confirms some of die earlier findings of 
association of cannabis use and the 
development of cannabis psychosis and 
schizophrenia, most significandy it reveals 
that heavy cannabis use can specifically 
cause a mania-like psychosis and more 
generally act as a precipitant for manic 
relapse in bipolar patients. 
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